Pembrolizumab is a humanized mAb against PD-1 approved by the FDA in 2014 after the KEYNOTE-001 clinical trial supported its efficiency in patients with unresectable or metastatic melanoma [18] and patients with NSCLC [19]. Here, PDCD1 is linked to metastatic melanoma.